Diagnostic methods
View Patent ↗This invention relates to a method of determining the susceptibility of an individual to statin-induced myopathy, comprising detecting the presence or absence of one or more polymorphisms in the SLCO1B1 gene in a biological sample from an individual, whereby the presence of one or more polymorphisms indicates that the individual has altered susceptibility to statin-induced myopathy.
1. A method comprising the steps of:
assaying, with a primer comprising a polynucleotide sequence set forth in SEQ ID NO: 20, for a presence of a cytosine (C) allele at single nucleotide polymorphism (SNP) rs4149056 in the SLCO1B11 gene in a sample obtained from a patient;
detecting the presence of a C allele in the sample; and
determining that the patient has an increased risk of statin-induced myopathy based on the presence of the C allele in the sample.
2. The method of claim 1 , wherein said assaying step comprises amplifying exon 6 of the SLCO1B1 gene comprising the SNP rs4149056.
3. The method of claim 1 , wherein said sample is a biological sample selected from the group consisting of individual cells, cell populations, bodily tissues, and bodily fluids.
4. The method of claim 1 , wherein said patient is also taking amiodarone, cyclosporine, or gemfibrozil.
5. The method of claim 1 , further comprising based on the determining step, administering 20 mg/daily of simvastatin or 40 mg/daily of simvastatin.
6. The method of claim 1 , further comprising based on the determining step, administering 10-20 mg/daily of atorvastatin.
7. The method of claim 1 , further comprising based on the determining step, administering 40-80 mg/daily of fluvastatin.
8. The method of claim 1 , further comprising based on the determining step, administering 40 mg/daily of lovastatin.
9. The method of claim 1 , further comprising based on the determining step, administering 40 mg/daily of pravastatin.
10. The method of claim 1 , further comprising based on the determining step, administering is 2 mg/daily of pitavastatin.
11. The method of claim 1 , further comprising based on the determining step, administering 10 mg/daily of rosuvastatin.
12. A method for prospectively identifying a patient at risk of statin-induced myopathy, the method comprising the steps of:
(a) obtaining nucleic acid from a patient who is not taking a statin;
(b) amplifying at least part of a SLCO1B1 gene in the nucleic acid using primers adapted to amplify single nucleotide polymorphism (SNP) rs4149056 in the SLCO1B1 gene, the primers including a primer comprising a polynucleotide sequence set forth in SEQ ID No. 20;
(c) identifying two thymines (TT) at SNP rs4149056 in the SLCO1B1 gene; and
(d) determining that the patient is at low risk for developing myopathy when taking a statin, based on the identifying of TT at SNP rs4149056 in the SLCO1B1 gene.
13. The method of claim 1 , wherein the assaying step includes assaying with a primer comprising a polynucleotide sequence set forth in SEQ ID No. 21.
14. The method of claim 12 , wherein the amplifying step includes amplifying at least part of the SLCO1B1 gene with a primer comprising a polynucleotide sequence set forth in SEQ ID No. 21.